UCB SA (UCBNV)

UCBNV Neurology Immunology

BiotechSign Signal Grade

Signal Grade

62.6/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying

Publications

Clinical Activity

100

Pipeline Overview

Therapeutic Focus: Neurology Immunologysrc

Clinical Trial Activity

Clinical Trials
(ClinicalTrials.gov aggregate)

6 Phase 1, 7 Phase 2, 21 Phase 3, 1 Phase 4

Trial Phase Breakdown

PubMed Publications

Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Recent Publications

A multicenter Phase II randomized, placebo-controlled single-blind trial with the SV2A ligand seletracetam in photosensitive epilepsy patients. — Epilepsy Behav 2025 Mar Kasteleijn-Nolst Trenité D PMID 39827675
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial. — Lancet Gastroenterol Hepatol 2024 Apr Lindsay JO PMID 38340759
Systematic Literature Review: Ability of the IBDQ-32 to Detect Meaningful Change in Ulcerative Colitis Health Indicators. — Inflamm Bowel Dis 2024 Nov 4 Dubinsky M PMID 38150386
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). — BMJ Open 2022 Apr 1 Papamichael K PMID 35365535
Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial. — JAMA Netw Open 2021 Dec 1 Feil K PMID 34905009

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for UCB SA.

Full UCBNV Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.